Abstract
Despite advances in clinical diagnosis and increasing numbers of patients eligible for revascularisation, ischaemic stroke remains a significant public health concern accounting for 3.3 million deaths annually. In addition to recanalisation therapy, patient outcomes could be improved through cerebroprotection, but all translational attempts have remained unsuccessful. In this narrative review, we discuss potential reasons for those failures. We then outline the diverse, multicellular effects of ischaemic stroke and the complex temporal sequences of the pathophysiological cascade during and following ischaemia, reperfusion, and recovery. This evidence is linked with findings from prior cerebroprotective trials and interpreted for the modern endovascular era. Future cerebroprotective agents that are multimodal and multicellular, promoting cellular and metabolic health to different targets at time points that are most responsive to treatment, might prove more successful.
Original language | English |
---|---|
Pages (from-to) | 267-271 |
Number of pages | 5 |
Journal | Journal of Neurology, Neurosurgery and Psychiatry |
Volume | 94 |
Issue number | 4 |
DOIs | |
State | Published - 1 Apr 2023 |
Externally published | Yes |
Keywords
- clinical neurology
- neurosurgery
- pharmacology
- stroke